Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I6VU
|
|||
| Former ID |
DCL000109
|
|||
| Drug Name |
Enzastaurin
|
|||
| Synonyms |
LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 3 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 3 | [2], [3], [4] | ||
| Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 2 | [2], [4] | ||
| Central nervous system disease [ICD-11: 8A04-8D87; ICD-10: C71; ICD-9: 191] | Phase 1 | [2], [4] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H29N5O2
|
|||
| Canonical SMILES |
CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7
|
|||
| InChI |
1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
|
|||
| InChIKey |
AXRCEOKUDYDWLF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 170364-57-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10258360, 14811491, 33499842, 50653190, 57288469, 92722604, 99436960, 103240316, 104020050, 104425375, 118855345, 124756967, 125163772, 125434326, 126627253, 126666986, 131465124, 134338799, 134964387, 135237310, 135686208, 135686209, 135686224, 135686225, 136340265, 136367952, 136920322, 137248831, 137275839, 142964159, 143498272, 144115944, 144206918, 152134183, 152233034, 152258187, 152344347, 152344363, 160647023, 160814256, 162011915, 162037408, 162191234, 162801883, 163372664, 163894051, 164840960, 170465609, 172913635, 174527910
|
|||
| ChEBI ID |
CHEBI:91368
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5693). | |||
| REF 3 | The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83. | |||
| REF 4 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.